Cytokine regulatory effects on α‐1 proteinase inhibitor expression in NOD mouse islet endothelial cells

Human microvascular islet endothelial cells (IEC) exhibit specific morphological and functional characteristics that differ from endothelia derived from other organs. One of these characteristics is the expression of α‐1 proteinase inhibitor (Api). In this study, we observed its expression in nonobese diabetic (NOD) mouse IEC, in relation to the occurrence of type 1 diabetes and in response to cytokines, namely IL‐1β and IL‐10. In addition, IL‐10‐deficient NOD mice as well as IL‐10 transgenic NODs were studied. Results have demonstrated that Api expression is: (i) highly specific for IEC in NOD mouse islets, as for humans; (ii) linked to the occurrence of early type 1 diabetes, and iii) strongly modulated by Th1 and Th2 cytokines. In fact, Api mRNA found in pre‐diabetic NOD animals is significantly reduced when they become hyperglycemic and disappears by 25 weeks of age, when mice are diabetic. Moreover, Api mRNAs are never seen in nondiabetic controls. Furthermore, in cultured NOD IEC, Api expression is downregulated by the addition of IL‐1β and is upregulated by IL‐10; it is always absent in IL‐10‐deficient NOD mice and overexpressed in IL‐10 transgenic NODs, thus further supporting that this cytokine upregulates Api expression. J. Cell. Biochem. 85: 123–130, 2002. © 2002 Wiley‐Liss, Inc.

[1]  D. Heistad,et al.  IL-10 deficiency increases superoxide and endothelial dysfunction during inflammation. , 2000, American journal of physiology. Heart and circulatory physiology.

[2]  N. Sarvetnick,et al.  Islet-Specific Expression of IL-10 Promotes Diabetes in Nonobese Diabetic Mice Independent of Fas, Perforin, TNF Receptor-1, and TNF Receptor-2 Molecules1 , 2000, The Journal of Immunology.

[3]  N. Sarvetnick,et al.  IL-10 deficiency does not inhibit insulitis and accelerates cyclophosphamide-induced diabetes in the nonobese diabetic mouse. , 2000, Cellular immunology.

[4]  C. Wollheim,et al.  Expression of alpha-1 proteinase inhibitor in human islet microvascular endothelial cells. , 1999, Diabetes.

[5]  C. Bristow,et al.  Specific Activity of α1Proteinase Inhibitor and α2Macroglobulin in Human Serum: Application to Insulin-Dependent Diabetes Mellitus , 1998 .

[6]  C. Cailleau,et al.  Treatment With Neutralizing Antibodies Specific for IL-1β Prevents Cyclophosphamide-Induced Diabetes in Nonobese Diabetic Mice , 1997, Diabetes.

[7]  N. Sarvetnick,et al.  The paradoxical effects of interleukin 10 in the immunoregulation of autoimmune diabetes. , 1996, Journal of autoimmunity.

[8]  H. Weiner,et al.  Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. , 1995, The American journal of pathology.

[9]  C. Suschek,et al.  Primary cultures of rat islet capillary endothelial cells. Constitutive and cytokine-inducible macrophagelike nitric oxide synthases are expressed and activities regulated by glucose concentration. , 1994, The American journal of pathology.

[10]  M. Monahan,et al.  Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. , 1994, Clinical immunology and immunopathology.

[11]  N. Sarvetnick,et al.  Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice , 1994, The Journal of experimental medicine.

[12]  G. Papaccio.  Insulitis and islet microvasculature in type 1 diabetes. , 1993, Histology and histopathology.

[13]  G. Papaccio,et al.  Alterations of islet microvasculature in mice treated with low-dose streptozocin , 1992, Histochemistry.

[14]  R. Cotran,et al.  The role of endothelial cells in inflammation. , 1990, Transplantation.

[15]  S. Bonner-Weir,et al.  β → α → δ Pancreatic Islet Cellular Perfusion in Dogs , 1988, Diabetes.

[16]  V. Marks,et al.  The order of islet microvascular cellular perfusion is B----A----D in the perfused rat pancreas. , 1988, The Journal of clinical investigation.

[17]  D. Wakefield,et al.  The role of α1-antitrypsin deficiency in the pathogenesis of immune disorders , 1985 .

[18]  L. Orci,et al.  New Perspectives on the Microvasculature of the Islets of Langerhans in the Rat , 1982, Diabetes.

[19]  G. Papaccio,et al.  Capillary area in early low-dose streptozocin-treated mice , 2004, Histochemistry.

[20]  M. Latronico,et al.  Adhesion molecules and microvascular changes in the nonobese diabetic (NOD) mouse pancreas. An NO-inhibitor (L-NAME) is unable to block adhesion inflammation-induced activation. , 1998, Autoimmunity.

[21]  M. Sandler,et al.  Serum alpha 1-protease inhibitor in diabetes mellitus: reduced concentration and impaired activity. , 1988, Diabetes research and clinical practice.

[22]  R. Stewart,et al.  Serum alpha-1-protease inhibitor activity and pulmonary function in young insulin-dependent diabetic subjects. , 1987, Respiration; international review of thoracic diseases.

[23]  D. Wakefield,et al.  The role of alpha 1-antitrypsin deficiency in the pathogenesis of immune disorders. , 1985, Clinical immunology and immunopathology.